(Albany, New York, USA) September 05, 2026- DelveInsight’s “COVID-19 Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the COVID-19 Pipeline @ COVID-19 Pipeline Outlook
Key Takeaways from the COVID-19 Pipeline Report
Get insights into COVID-19 clinical trials, emerging therapies, and leading companies with DelveInsight @ COVID-19 Treatment Drugs
The COVID-19 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The COVID-19 Pipeline Report also highlights the unmet needs with respect to the COVID-19.
COVID-19 Overview
COVID-19 is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus. COVID-19 has had a catastrophic effect on the world, resulting in more than 6 million deaths worldwide. Like other RNA viruses, SARS-CoV adapts with genetic evolution and developing mutations. This results in mutant variants that may have different characteristics than their ancestral strains. The symptoms of COVID-19, caused by SARS-CoV-2, vary widely in severity, ranging from asymptomatic infection to severe respiratory illness. The most common symptoms include fever, dry cough, fatigue, and shortness of breath, often accompanied by sore throat, headache, and muscle aches. Many individuals also experience loss of taste or smell, which became a distinguishing feature of the disease. In some cases, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur. Severe cases can progress to pneumonia, chest pain, confusion, and difficulty breathing, potentially leading to acute respiratory distress and multi-organ complications.
COVID-19 Emerging Drugs Profile
VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd’s proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.
Ibuzatrelvir (PF-07817883) is an investigational, second-generation oral SARS-CoV-2 main protease inhibitor developed by Pfizer to treat COVID-19. It acts as a single agent without requiring ritonavir boosting, offering a potential advantage in reducing drug-drug interactions, and has shown significant viral reduction in Phase 2 trials. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of COVID-19.
N-803 is an interleukin-15 superagonist fusion protein that is designed to induce expansion of native NK and CD8+ T-cells without concurrent stimulation of T-regulatory cells and (Aldox) is a proprietary albumin-bound doxorubicin complex that is designed to preferentially accumulate in a tumor’s low pH environment. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.
ENTVAX002 (also known as Covigenix VAX-002) is an investigational, next-generation COVID-19 booster vaccine developed by Entos Pharmaceuticals in partnership with Aegis Life. It is a plasmid DNA (pDNA) vaccine specifically engineered to combat emerging SARS-CoV-2 Omicron variants, utilizing the company’s proprietary Fusogenix proteo-lipid vehicle (PLV) platform for delivery. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.
ALG-097558 is a potent ritonavir-free pan-coronavirus protease inhibitor (PI). In preclinical studies, ALG‑097558 has been shown to be at least 6-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants. It has demonstrated broad pan-coronavirus activity, including against SARS and MERS. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of COVID-19.
RBM001 is a low-sugar, broad-spectrum COVID-19 protein vaccine developed by Rock BioMedical, a Taiwan-based biotech company. The vaccine is designed to address rapidly mutating viruses by removing glycan shields from the spike protein, exposing highly conserved, less-mutable areas to the immune system, thus providing wider protection against various strains. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.
MDX2301 is a multispecific antibody therapy for the prevention of COVID-19 designed to neutralize diverse SARS-CoV-2 variants. The ModeX multispecific antibody format enables the rational combination of multiple binding sites in a single antibody, aiming to broaden coverage against current and future viral variants while enabling potent neutralization and the potential for enhanced therapeutic efficacy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.
PA-001, a peptide-based inhibitor targeting the S2 domain of the SARS-CoV-2 spike protein, a protein essential for coronavirus entry into human cells. The S2 region is highly conserved across variants and subvariants, and PA-001 demonstrated potent activity against all major variants from Wuhan to Omicron BA.5. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of COVID-19.
Explore groundbreaking therapies and clinical trials in the COVID-19 Pipeline @ New COVID-19 Drugs
The COVID-19 Pipeline Report Provides Insights into
COVID-19 Companies
Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
COVID-19 Products have been categorized under various Molecule types such as
Learn about new COVID-19 drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ COVID-19 Market Drivers and Barriers
Scope of the COVID-19 Pipeline Report
Download DelveInsight’s in-depth pipeline report today! @ COVID-19 Companies, Key Products and Unmet Needs
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/covid-19-pipeline-insight
